Android app on Google Play

Deutsche Bank Sees Chelsea Therapeutics (CHTP) Risk Skewed to the Downside ahead of Northera Approval

January 15, 2014 8:19 AM EST Send to a Friend
Get Alerts CHTP Hot Sheet
Price: $6.52 --0%

Rating Summary:
    1 Buy, 5 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 24 | New: 21
Trade CHTP Now!
Join SI Premium – FREE
Deutsche Bank analyst Robyn Karnauskas bumped her price target on Chelsea Therapeutics (NASDAQ: CHTP) from $4 to $5 but maintained a Hold rating following a positive FDA AdCom on Northera. The analyst sees 30% upside and 70% downside into approval.

Karnauskas said the 16 to 1 AdCom vote was positive in the light of negative documents posted by the FDA before the panel. She sees fair value at $8-9/sh if the FDA approves Northera, although she is recommending investors remain on the sidelines given that the FDA had previously decided against the approval after a positive panel in March-2012.


price target of $5.00 (from $4.00)

For an analyst ratings summary and ratings history on Chelsea Therapeutics click here. For more ratings news on Chelsea Therapeutics click here.

Shares of Chelsea Therapeutics closed at $2.30 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities

Deutsche Bank

Add Your Comment